



Test Description

PROMETHEUS[®] Celiac Serology is a comprehensive serum antibody profile. By combining important serologic markers for diagnosing celiac disease and utilizing a 5-marker panel including deamidated gliadin peptides, EMA-IgA and tTG-IgA, this test offers reliable and consistent results from a recognized leader in celiac testing. Knowledge of serologic markers may help detect celiac disease by providing serologic answers.

- An evaluation of antibodies associated with celiac disease to assist physicians with diagnosis and dietary compliance
- **Specimen Requirements** - 2.0 ml Serum, SST or Red Top Tube
- **Shipping Requirements** - Ambient or cold pack
- **Storage /Stability** – 7 days ambient, 30 days refrigerated
- **Turn Around Time** – 2-3 business days from date of receipt

Test Information

Catalog Number	Test Name	Assay	Reference Value	Result Identifier*
1155	Celiac Serology	Deamidated Gliadin Peptide Antibody, IgG (DGP IgG)	<4.9 EU/mL	A00034
		Deamidated Gliadin Peptide Antibody, IgA (DGP IgA)	<6.1 EU/mL	A00035
		Anti-Human Tissue Transglutaminase IgA ELISA (TTG IgA)	<10.3 U/mL	A00013
		Anti-Endomysial IgA IFA (EMA IgA)	Negative	A00003
		Total Serum IgA by Nephelometry (Total IgA)	<3 years: 8-220 mg/dL; 3-13 years: 41-395 mg/dL; >13 years: 44-441 mg/dL	A00012

*Result identifier provided for use in HL7 applications.

Laboratory Description

- Prometheus is located in San Diego, CA. **Tax ID#** 33-0685754 **NPI#** 1073642641.
- Licensed in several states including New York and California.
- This test was developed and its performance characteristics determined by Prometheus Laboratories Inc. It has not been cleared or approved by the U.S. Food and Drug Administration. Prometheus Laboratories Inc. is a CAP-accredited CLIA laboratory.

CPT Codes (as applied by Prometheus)

- **83520(X3)**, ELISA; antibody specific (Deamidated Gliadin Peptide IgA, Deamidated Gliadin Peptide IgG, Anti-Tissue Transglutaminase IgA)
- **88346(X1)**, Anti-Endomysial (EMA) IgA Antibody by IFA
- **82784(x1)**, Total Serum IgA, by Nephelometry

Literature References

- Fasano A, Berti I, Gerarduzzi T, et al. Prevalence of celiac disease in at-risk and not-at-risk groups in the United States. *Arch Intern Med.* 2003;163:286-292.
- Green PHR, Jabri B. Coeliac disease. *Lancet.* 2003;362(9381):383-391.
- Mothes, T., Deamidated Gliadin Peptides as Targets for Celiac Disease-Specific Antibodies; *Advances in Clinical Chem*, 2007; Vol. 44, 35-63.

Assays and methods within this test may be covered by one or more US pending or issued patents. For details, please visit www.prometheuslabs.com